Compare Cytokinetics Inc (CYTK) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard S&P 500 ETF — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while Vanguard S&P 500 ETF trades at $709.48. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | VOO | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $710.71 |
52-Week Low | $34.31 | $580.93 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
VOO (Vanguard S&P 500 ETF) trades at $710.71, up 0.6% with a bullish technical signal from moving averages. The ETF tracks the S&P 500 index, which recently reclaimed record highs amid strong corporate earnings and AI-driven optimism. Technical indicators show overbought conditions with RSI at 94.45 on the 6-day timeframe, while support levels begin at $708. JPMorgan raised its S&P 500 year-end target to 8,000, citing earnings strength and AI investment payoffs.
The outlook remains positive given robust earnings growth and institutional confidence, though near-term consolidation risks exist from overbought technicals and valuation concerns. Key risks include market breadth weakness and potential September volatility. The ETF's low-cost structure and diversification continue to attract long-term investors seeking S&P 500 exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
